Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorLancaster General Hospital
About this trial
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
Eligibility criteria
Qualifiers
Male or female age ≥ 18 years
Confirmed diagnosis of non-ischemic DCM determined at the discretion of the treating physician and defined as LVEF ≤ 45% at any time during the clinical course of the patient
Must have at least one living adult FDR
Able to provide informed consent
Disqualifiers
DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination
Proband has previously informed FDR to undergo cardiac screening
Ischemic cause of reduced LVEF
evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease
Trial design
Treatments tested in this trial
- Mobile 6L AI-EKG Screening
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
Lancaster General Hospital
Lead sponsor
Mayo Clinic
Collaborator
Source ClinicalTrials.gov